The objective of this observational study is to evaluate the effectiveness of the dietary supplementation "OnLife" in improving signs and symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in adult patients who have finished adjuvant oxaliplatin-containing regimen (colon cancer) or adjuvant paclitaxel regimen (breast cancer). Furthermore, patient-reported outcomes (PROs) and concomitant medication used for the treatment of neuropathic pain will be assessed.
No linked publications found in PubMed
Inclusion Criteria: * Adult patients with colon or breast cancer that have finished adjuvant oxaliplatin-containing or paclitaxel chemotherapy, respectively * End of adjuvant chemotherapy does not date back more than 4 months * Presence of CIPN grade 1-3 (according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03) * Decision for treatment with OnLife® (Baseline assessment has to be done before first intake of OnLife®) * Written informed consent * Able to understand and willing to complete study and patient-reported assessment instruments Exclusion Criteria: * Presence of sensory and/or motor disturbances due to other neurological diseases * Alcohol abuse * Pregnancy or breast-feeding * Severe difficulty swallowing * Intolerance to one of the ingredients of OnLife®